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ABSTRACT 
Background: Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate with limited 
treatment options. Gemcitabine provides a marginal survival benefit for patients with advanced 
PDAC. Dasatinib is a competitive inhibitor of Src kinase, which is overexpressed in PDAC 
tumors. Dasatinib and gemcitabine were combined in a phase 1 clinical trial where stable 
disease was achieved in 2 of 8 patients with gemcitabine-refractory PDAC. 
Patients and methods: This placebo-controlled, randomized, double-blind, phase II study 
compared the combination of gemcitabine plus dasatinib to gemcitabine plus placebo in patients 
with locally advanced, non-metastatic PDAC. Patients received gemcitabine 1,000 mg/m2 (30-
minute IV infusion) on days 1, 8, 15 of a 28-day cycle combined with either 100 mg oral 
dasatinib or placebo tablets daily. The primary objective was overall survival (OS), with safety 
and progression-free survival (PFS) as secondary objectives. Exploratory endpoints included 
overall response rate, freedom from distant metastasis, pain and fatigue progression and 
response rate, and CA19-9 response rate. 
Results: There was no statistically significant difference in OS between the 2 treatment groups 
(HR = 1.16; 95% confidence interval [CI]: 0.81–1.65; p=0.5656). Secondary and exploratory 
endpoint analyses also showed no statistically significant differences. The burden of toxicity was 
higher on the dasatinib arm. 
Conclusions: Dasatinib failed to show increased OS or PFS in patients with locally advanced 
PDAC. Alternative combinations or trial designs may show a role for src inhibition in PDAC 
treatment. 
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Key message: Adding dasatinib to gemcitabine did not improve progression-free or overall 
survival in patients with locally advanced inoperable, non-metastatic pancreatic cancer. 
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BACKGROUND 
Pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive invasion and early 
metastases. Overall survival remains poor in patients with inoperable, locally advanced, or 
metastatic PDAC. Gemcitabine remains one therapeutic option for patients with advanced 
PDAC and provides a marginal survival advantage [1, 2]. Among other therapeutic options, two 
combination regimens have further extended survival prolongation of gemcitabine [3, 4]. 
Chemoradiation may increase locoregional control in PDAC (at the cost of considerable 
toxicity), but this approach does not address the principal mode of treatment failure in locally 
advanced PDAC, which is development of distant metastases. 
Src-family kinases are non-receptor tyrosine kinases with a critical role in cellular proliferation 
[5-7]. Src is involved in many aspects of tumor cell behavior that influence metastatic capacity, 
such as survival, adhesion, migration, and invasion. Furthermore, Src is over-expressed in 
PDAC [8, 9]. Compared with normal pancreatic ducts, increased expression and activation of 
Src were observed in 74% and 60% of tumors, respectively, correlating with reduced survival in 
resected PDAC [10]. Moreover, gemcitabine chemo-resistance in PDAC cell lines was 
associated with increased Src kinase activity [11]. Src kinase inhibition enhances gemcitabine-
induced cytotoxicity in vitro, and significantly increases tumor growth inhibition in orthotopic 
models in vivo in combination with gemcitabine compared to either agent alone [11].  
Dasatinib, a competitive inhibitor of Src and Abl kinases [12, 13], represents an effective therapy 
for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic 
leukemia [14-18]. Treatment of pancreatic cancer cell lines in vitro with dasatinib inhibits 
invasion and migration at concentrations that inhibit Src kinase activity [10, 19], as well as 
proliferation and anchorage-independent cell growth [19, 20]. Dasatinib inhibits pancreatic tumor 
growth in vivo in xenograft models [19, 20] and inhibits the development of metastases in vivo in 
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a genetically-engineered mouse model of pancreatic cancer [10], suggesting that this agent 
might best be used in patients without metastatic disease to prevent development of distant 
metastases. Unpublished data from the first author’s laboratory suggests that there was a trend 
to improved overall survival with the combination of gemcitabine and dasatinib compared to 
dasatinib alone in a genetically-engineered mouse model of pancreatic cancer that did not reach 
statistical significance (p = 0.08). 
Dasatinib and gemcitabine were combined in 2 phase 1 clinical trials. In the first study, 
recommended combination doses were dasatinib 100 mg by mouth (PO) daily and gemcitabine 
600 mg/m2 intravenously (IV) weekly for the first 7 of 8 weeks, and dose limiting toxicities 
included fatigue and dehydration [21]. Stable disease was achieved in 2 of 8 patients with 
gemcitabine-refractory PDAC. In a second phase 1 combination trial, recommended 
combination doses were dasatinib 100 mg daily by mouth, and gemcitabine 1,000 mg/m2  for 3 
weeks out of 4 and dose-limiting toxicities included neutropenia with infection, elevation of ALT, 
and pneumonitis [22]. The current phase 2 clinical trial compared the combination of 
gemcitabine plus dasatinib to gemcitabine plus placebo in patients with locally advanced, non-
metastatic PDAC. The primary objective was overall survival (OS), with comparison of safety 
and progression-free survival (PFS) as secondary objectives. Exploratory objectives included 
freedom from distant metastases (FFDM), pain, fatigue, CA19-9 response rates, and objective 
responses. 
PATIENTS AND METHODS 
Patients 
This placebo-controlled, randomized, double-blind, multi-center, phase II study was conducted 
in accordance with Good Clinical Practice (GCP) guidelines and approved by the research 
ethics committees at each of the participating institutions. All patients provided written, informed 
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consent prior to undergoing any study-related procedures. 
Eligible patients had pathologically-proven PDAC with unresectable disease due to local 
extension, invasion, or lymph node involvement beyond the surgical field but had no evidence of 
metastatic disease based on imaging assessments. Additional eligibility criteria are included in 
supplementary information.  
Study Design 
Patients were randomized 1:1 to receive gemcitabine 1,000 mg/m2 (30-minute IV infusion) on 
days 1, 8, and 15 of a 28-day cycle combined with either 100 mg oral dasatinib (dasatinib 
group) or placebo tablets (placebo group) daily with breakfast (Figure 1). Stratification factors 
included baseline ECOG PS of 0 versus 1 and intent to administer radiotherapy (yes/no). At the 
investigator’s discretion, patients without evidence of metastatic disease after 6 cycles of 
treatment had the option to receive radiotherapy with conventional fractionation with or without 
concomitant 5-FU or capecitabine chemotherapy starting within 3 weeks of cycle 6 study 
therapy. Gemcitabine and dasatinib/placebo were interrupted during radiotherapy and resumed 
within 6 weeks after radiotherapy completion. Study treatment continued until progressive 
disease (PD), withdrawal of consent, or unacceptable toxicity. 
Dose delays and dose modifications were based on observed toxicities (supplementary 
methods Tables S1-S3) and subsequent treatment is described in supplementary information.  
Evaluations and Response Assessment 
Pre-treatment evaluation included a complete history and physical examination, vital signs, 
assessment of PS, blood counts, biochemical profile, coagulation screen, electrocardiograms, 
serum CA19-9 analysis, urinalysis, pregnancy test (if appropriate), and assessment of pain and 
fatigue (10-point numeric scales). Toxicity was graded using the National Cancer Institute 
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Common Toxicity Criteria (NCI-CTCAE) Version 3.0. 
Radiologic studies to evaluate disease sites were performed within 14 days prior to dosing on 
day 1, and every 8 weeks until disease progression, determined by RECIST v1.1 [23]. Other 
assessments are included in supplementary information.  
Statistical Hypothesis and Analyses 
All analyses were performed on an intent-to-treat basis. OS was determined from the date of 
randomization until death (any cause) and analyzed by the log rank method. Hazard ratio was 
estimated using the Cox proportional hazards model with the following predictors: treatment, 
baseline ECOG, geographical region, CA19-9, and whether radiotherapy was received during 
the trial. A sample size of 200 patients was sufficient to demonstrate an increase in median OS 
from 10 to 13.3 months (Hazard Ratio [HR] = 0.75) with 79% power using a 1-sided α of 0.2. 
This sample size would have 88% power to detect an increase in PFS from 5 to 7 months (HR = 
0.714; 1 sided α = 0.15). 
PFS was defined as the time from randomization until local or distant disease progression 
(RECIST v1.1). Additional analyses are included in the supplementary information.   
RESULTS 
Patients 
A total of 280 patients were screened, and 202 patients were enrolled at 79 trial sites in 15 
countries in Australasia, Europe, and North America (Figure 2). Intent-to-treat groups for 
analysis consisted of 100 patients assigned to receive gemcitabine plus dasatinib (dasatinib 
group) and 102 assigned to receive gemcitabine plus placebo (placebo group). Three patients, 
2 in the dasatinib group and 1 in the placebo group, did not receive study treatment and were 
not included in safety analyses. 
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Median age of enrolled patients was 65 years (range 37-87), and 51% were male (Table 1). A 
higher proportion of patients were male in the dasatinib arm (57% vs 45%). ECOG PS was 
evenly distributed between groups with approximately 61% of patients in each group having a 
score of 1. Other prognostic factors were balanced, except that more patients in the dasatinib 
group had stage II disease (75% vs 68%). Median treatment duration of treatment with dasatinib 
or placebo was 4 and 5 cycles, respectively. Dose reduction of dasatinib was required in 34% of 
patients, and of placebo in 23% of patients. Median gemcitabine treatment duration was 
5 cycles in both dasatinib and placebo groups. Dose reduction of gemcitabine was required in 
42% of patients in each of the two groups. Radiotherapy was administered in 37 patients (18, 
dasatinib group; 19, placebo group), and more than 90% of the planned radiotherapy dose was 
administered in 34 patients. Concomitant chemotherapy was administered in 31 patients (12, 
dasatinib; 19, placebo), and more than 90% of the planned radio-sensitizing chemotherapy was 
administered in 27 patients. 
Efficacy Analyses 
At the data cut-off date of December 2, 2013, there was no significant difference in OS between 
the dasatinib and placebo groups (375 days vs 393 days, HR = 1.16; 95% confidence interval 
[CI]: 0.81–1.65; p=0.5656) (Figure 3A, Table 2). There was also no significant difference in the 
median PFS of 167 and 166 days for dasatinib- and placebo-treated patients, respectively (HR 
= 1.03; 95% CI: 0.76–1.39; p=0.8731) (Figure 3B). Additionally, in a population exclusive of 
patients with treatment discontinuation for reasons other than disease progression, median PFS 
was 221 and 218 days for dasatinib- and placebo-treated patients, respectively (HR = 0.99; 
95% CI: 0.68–1.43; p=0.7058). 
Overall response rates were 11% in the dasatinib group and 8% in the placebo-treated group 
(p=0.4392) (Table 2). No statistical difference was observed in other exploratory endpoints, 
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including FFDM, pain progression, pain response, fatigue response, and CA19-9 response 
rates. A statistically non-significant difference was observed in median FFDM at 310 days for 
dasatinib- (n= 32/99) and 380 days for placebo- (n= 32/102) treated patients (p=0.7994). There 
was no difference in the CA 19-9 response. 
Safety analysis 
Treatment-emergent adverse events (TEAEs) of any cause occurred in 99% and 98% of 
patients in dasatinib and placebo groups, respectively (Table 3). In the dasatinib group, TEAEs 
Grade 3 occurring in ≥10% of patients include neutropenia (33% of patients), fatigue (16%), 
thrombocytopenia (13%), anemia (12%), and abdominal pain (10%); in the placebo group, they 
include neutropenia (26%) and thrombocytopenia (11%). Potential treatment-related AEs were 
more common in the dasatinib group (79% vs 64% of patients) (See supplemental results table). 
Overall, 31 patients (32%) in the dasatinib group discontinued treatment due to an AE versus 25 
patients (25%) in the placebo group. The most common TEAEs leading to treatment 
discontinuation in dasatinib and placebo groups include pleural effusion (2 and 2 patients), 
peripheral edema (2 and 1), and vomiting (2 and 0), respectively. 
Cardiopulmonary events have been noted for drugs in this class. No QT prolongation or 
ventricular arrhythmia events were reported. Hemorrhage, cardiac disorders, thromboembolic 
events, and pulmonary arterial hypertension were infrequent. Myelosuppression was frequent, 
occurring more within the dasatinib group (52% vs 29%). Fluid retention also occurred 
frequently, with both peripheral edema and pleural effusions being more common in the 
dasatinib group (34% vs 21% and 27% vs 7%, respectively). Additional safety analyses are 
included in the supplementary information.  
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DISCUSSION 
In vitro and in vivo studies support a role for dasatinib in inhibiting the development of 
metastases in PDAC. Dasatinib decreases cell proliferation, cell cycle progression, anchorage 
independent growth, migration, and invasion in PDAC cell lines in vitro [10, 19] and significantly 
inhibited the development of metastases in vivo with no effect on overall survival, probably due 
to progression of the primary tumor. Thus, there is evidence to support the hypothesis that Src 
kinase inhibitors may function as anti-metastatic agents in PDAC [10]. Consequently, this study 
was designed to determine if dasatinib could inhibit the development of metastases and improve 
overall survival if the growth of the primary tumor could be adequately controlled by gemcitabine 
in patients with inoperable, locally advanced, non-metastatic PDAC. Combined chemotherapy 
and radiotherapy could be administered (intention to treat prior to randomisation) at the 
investigator’s discretion to maximise recruitment across international sites in some of which 
chemo-radiation was standard of care for this patient population. Our study was closed to 
recruitment prior to the first presentation of the LAP-07 study [24]. Nevertheless, the hypothesis 
of our study was that the addition of dasatinib would inhibit the development of metastases, 
thereby improving survival, if local disease control was optimised. The combination of 
chemotherapy and radiotherapy may still have a role in optimising local control, even if the 
results of the LAP 07 study suggests that this does not lead to a survival benefit.  
 
Addition of dasatinib to gemcitabine did not improve overall survival of patients with locally-
advanced pancreatic cancer in this study versus placebo in combination with gemcitabine. 
Secondary and exploratory endpoint analyses, including PFS, overall response rate, FFDM, 
pain progression and response rate, fatigue progression and response rate, and CA19-9 
response rate also showed no statistically significant differences between the two groups. 
Observed toxicities were consistent with the known safety profiles of dasatinib and gemcitabine 
 11 
in patients with solid tumors and revealed no new safety concerns [13, 21, 25]. 
Several possible explanations account for the lack of a survival benefit in this study. First, 
recommended doses from the phase I study were dasatinib 100 mg PO daily and gemcitabine 
600 mg/m2 IV weekly for 7 of the first 8 weeks [21]. We used a higher dose of gemcitabine 
(1,000 mg/m2 on days 1, 8, 15 of a 28-day cycle) as we were concerned that a dose of 600 
mg/m2 IV weekly would be sub-therapeutic as first-line therapy of patients with PDAC when 
combined with a placebo in this double-blind study. Patients treated with 1,000 mg/m2 of 
gemcitabine in combination with dasatinib had a higher incidence of Grade 3 TEAEs, as well as 
of TEAEs that led to treatment discontinuation. In addition, fewer patients in the dasatinib group 
completed dosing cycles for both dasatinib and gemcitabine treatment compared with the 
placebo group. Therefore, it may be that because this combination was not well tolerated, 
administration of adequate chemotherapy for control of the primary tumor and of dasatinib to 
inhibit development of metastases may have been compromised. 
Data on subsequent treatments administered was not routinely collected after disease 
progression, a trial-specific endpoint for treatment discontinuation, was met. However, we think 
it is unlikely that any imbalance in second-line treatments between the two treatment arms will 
have obscured any significant difference in overall survival in the absence of any significant 
difference in progression-free survival with study therapy, especially given the modest, if any, 
survival benefit with second-line therapy in this disease at the time that the study was 
conducted. 
Newer combination chemotherapy regimens, such as FOLFIRINOX, generate higher objective 
response rates and disease control in patients with metastatic disease. A more appropriate 
future study design to test the hypothesis that dasatinib inhibits the development of metastases 
may be to administer dasatinib as “maintenance” therapy, sequentially rather than in 
combination, after optimal control of localized non-metastatic disease with this more active 
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chemotherapy regimen. For example, maintenance treatment with sunitinib in pancreatic 
adenocarcinoma may have inhibited the development of metastases and improved 2-year 
survival [26]. Alternatively, it may be more appropriate to evaluate dasatinib as a post-operative 
adjuvant treatment to improve overall survival by inhibiting metastases [2]. Although we enrolled 
patients without clinically- or radiologically-visible metastases in our study, it is possible that 
sub-clinical metastases were already present. Dasatinib may be more effective at inhibiting 
presumed micro-metastatic disease following potentially curative resection.  
There is little evidence to support that Src pathway activation is a predictive marker for dasatinib 
activity. Given the paucity of archival tumour material that is invariably available for patients with 
inoperable, non-metastatic pancreatic cancer, and the lack of a robust predictive marker 
hypothesis, we did not think it justified to pursue mandatory additional pre-treatment tumor 
biopsies for exploratory research in this study 
In conclusion, addition of dasatinib to gemcitabine failed to increase OS or PFS in patients with 
locally-advanced PDAC. Because this trial did not include pharmacodynamics, it is not possible 
to conclude whether dasatinib penetration of the tumor was adequate to inhibit tumoral Src. 
Conversely, the dasatinib-gemcitabine combination generated increased toxicity relative to 
gemcitabine alone. This toxicity burden led to earlier discontinuation of combination therapy and 
likely contributed to the failure to improve OS. Alternative clinical trial designs with other drug 
combinations or sequenced schedules of administration could be pursued to further define a 
role for Src inhibition in PDAC treatment via metastasis inhibition. 
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Table 1. Baseline Patient Characteristics. 
 
Dasatinib + 
Gemcitabine 
(n=100) 
Placebo + 
Gemcitabine 
(n=102) 
Total 
(n=202) 
Age, median (range) 65 (37–86) 66 (38–87) 65 (37–87) 
Sex, n (%)    
 Male 57 (57) 46 (45) 103 (51) 
 Female 43 (43) 56 (55) 99 (49) 
Race, n (%)    
 White 96 (96) 93 (91) 189 (94) 
 Black 1 (1) 5 (5) 6 (3) 
 Asian 1 (1) 0 1 (1) 
 Other 2 (2) 4 (4) 6 (3) 
ECOG performance score, n (%)    
 0 37 (37) 39 (38) 76 (38) 
 1 61 (61) 62 (61) 123 (61) 
Tumor stage, n (%) a    
 ≤ IIB 24 (24) 33 (32) 57 (28) 
 III 75 (75) 69 (68) 144 (71) 
Tumor location, n (%) b    
 Head 75 (75) 77 (76) 152 (75) 
 Body 25 (25) 32 (31) 57 (28) 
 Tail 9 (9) 8 (8) 17 (8) 
Radiotherapy intent, n (%)    
 Yes 49 (49) 49 (48) 98 (49) 
 No 51 (51) 53 (52) 104 (52) 
ECOG, Eastern Cooperative Oncology Group. 
a. In addition, 1 patient in the dasatinib + gemcitabine arm did not have locally advanced stage 
tumor. 
b. Total numbers exceed the number of patients and percentages exceed 100 as the primary 
tumor location may be recorded as present at more than one site (e.g. head and body). 
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Table 2. Summary of Efficacy. 
 
Dasatinib + 
Gemcitabine 
(n = 100) 
Placebo + 
Gemcitabine 
(n = 102) 
HR a or  
Relative Risk c  
(95% CI) P-value b 
Progression-free survival     
 Number of events, n (%) 85 (85) 91 (89) 1.03 0.8731 
 Median, days (95% CI) 167 (114, 212) 166 (158, 199) (0.76, 1.39)  
Overall survival     
 Number of events, n (%) 69 (69) 66 (65) 1.16 0.5656 
 Median, days (95% CI) 375 (310, 462) 393 (356, 467) (0.81, 1.65)  
Freedom from distant metastasis     
 Number of events/n (%) 32/99 (32) 32/102 (31) 1.24 0.7994 
 Median, days (95% CI) 310 (246, 910) 380 (267, NA) (0.74, 2.07)  
Pain progression     
 Number of events (%) 16 (16) 23 (23) 0.68 0.2897 
 Median, days (95% CI) NA (371, NA) NA (NA, NA) (0.36, 1.31)  
Fatigue progression     
 Number of events (%) 22 (22) 24 (24) 1.04 0.9305 
 Median, days (95% CI) NA (329, NA) NA (296, NA) (0.58, 1.87)  
Overall response, n (%)     
 Number of events (%) 11 (11) 8 (8) 1.41 (0.592, 3.351) 0.4392 
Complete response     
 Number of events (%) 0 (0) 0 (0) NA NA 
Partial response     
 Number of events (%) 11 (11) 8 (8) 1.41 (0.592, 3.351) 0.4392 
Stable disease     
 Number of events (%) 68 (68) 75 (74) NA NA 
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Dasatinib + 
Gemcitabine 
(n = 100) 
Placebo + 
Gemcitabine 
(n = 102) 
HR a or  
Relative Risk c  
(95% CI) P-value b 
Progressive disease     
 Number of events (%) 9 (9) 13 (13) NA NA 
Pain response     
 Number of events (%) 24 (24) 24 (24) 1.02 (0.622, 1.673) 0.9371 
Fatigue response     
 Number of events (%) 13 (13) 22 (22) 0.61 (0.328, 1.149) 0.1105 
CA 19-9 response     
 Number of events/n (%) 36/96 (38) 35/98 (36) 1.06 d (0.726, 1.537) 0.8538 
CI, confidence interval. 
a. Hazard ratio and its confidence interval is obtained from Cox proportional hazard model with treatment, baseline ECOG PS, 
region, CA 19-9 (<1000 iu/ml, >=1000 iu/ml), and RT received during the trial (yes or no) as predictors. 
b. P-values are derived from log-rank test. 
c. Relative risk, 95% confidence interval for relative risk and p-value were derived from Cochran-Mantel-Haenszel model stratified by 
radiotherapy received during the study (yes or no). 
d. dRelative risk, 95% confidence interval for relative risk and p-value were derived from Cochran-Mantel-Haenszel model stratified 
by baseline CA 19-level (<1000 iu/ml, >=1000 iu/ml). 
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Table 3. Incidence of Treatment-Emergent Adverse Events Occurring in at Least 10% of Patients in Either Treatment Group (safety 
Population). 
 Dasatinib  +Gemcitabine 
(n = 98) 
Placebo +Gemcitabine 
(n = 101) 
Total 
(N=199) 
Adverse Event, n (%) All Grade Grade ≥3 All Grade Grade ≥3 All Grade Grade ≥3 
Nausea  66 (67) 2 (2) 49 (49) 1 (1) 115 (58) 3 (2) 
Neutropenia  53 (54) 32 (33) 49 (49) 26 (26) 102 (51) 58 (29) 
Fatigue  48 (49) 16 (16) 46 (46) 9 (9) 94 (47) 25 (13) 
Anemia  51 (52) 12 (12) 29 (29) 5 (5) 80 (40) 17 (9) 
Vomiting  43 (44) 4 (4) 36 (36) 2 (2) 79 (40) 6 (3) 
Thrombocytopenia  38 (39) 13 (13) 39 (39) 11 (11) 77 (39) 24 (12) 
Abdominal pain  35 (36) 10 (10) 37 (37) 2 (2) 72 (36) 12 (6) 
Diarrhea  42 (43) 6 (6) 29 (29) 1 (1) 71 (36) 7 (4) 
Decreased appetite  46 (47) 2 (2) 23 (23) 2 (2) 69 (35) 4 (2) 
Constipation  35 (36) 3 (3) 28 (28) 0 (0) 63 (32) 3 (2) 
Peripheral edema  33 (34) 5 (5) 21 (21) 1 (1) 54 (27) 6 (3) 
Pyrexia  22 (22) 1 (1) 31 (31) 2 (2) 53 (27) 3 (2) 
Dyspnea  27 (28) 3 (3) 20 (20) 4 (4) 47 (24) 7 (4) 
Increased alanine  
 aminotransferase  
22 (22) 9 (9) 14 (14) 3 (3) 36 (18) 12 (6) 
Rash  20 (20) 0 (0) 14 (14) 0 (0) 34 (17) 0 (0) 
Pleural effusion  26 (27) 6 (6) 7 (7) 0 (0) 33 (17) 6 (3) 
Asthenia  16 (16) 4 (4) 16 (16) 4 (4) 32 (16) 8 (4) 
Decreased weight  19 (19) 2 (2) 11 (11) 0 (0) 30 (15) 2 (1) 
Abdominal pain upper  9 (9) 2 (2) 18 (18) 0 (0) 27 (14) 2 (1) 
Increased aspartate  16 (16) 4 (4) 11 (11) 2 (2) 27 (14) 6 (3) 
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 Dasatinib  +Gemcitabine 
(n = 98) 
Placebo +Gemcitabine 
(n = 101) 
Total 
(N=199) 
Adverse Event, n (%) All Grade Grade ≥3 All Grade Grade ≥3 All Grade Grade ≥3 
 aminotransferase  
Insomnia  11 (11) 1 (1) 14 (14) 0 (0) 25 (13) 1 (1) 
Cough  12 (12) 0 (0) 13 (13) 0 (0) 25 (13) 0 (0) 
Increased blood alkaline  
 phosphatase  
15 (15) 9 (9) 8 (8) 2 (2) 23 (12) 11 (6) 
Hypokalemia  12 (12) 7 (7) 10 (10) 4 (4) 22 (11) 11 (6) 
Leukopenia  8 (8) 5 (5) 13 (13) 7 (7) 21 (11) 12 (6) 
Headache  12 (12) 0 (0) 9 (9) 0 (0) 21 (11) 0 (0) 
Blood bilirubin increased  13 (13) 5 (5) 6 (6) 3 (3) 19 (10) 8 (4) 
Dysgeusia  12 (12) 0 (0) 6 (6) 0 (0) 18 (9) 0 (0) 
Flatulence  6 (6) 0 (0) 11 (11) 0 (0) 17 (9) 0 (0) 
Alopecia  10 (10) 0 (0) 7 (7) 0 (0) 17 (9) 0 (0) 
Dizziness  4 (4) 0 (0) 11 (11) 1 (1) 15 (8) 1 (1) 
Anxiety  10 (10) 0 (0) 4 (4) 0 (0) 14 (7) 0 (0) 
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Figure 1. Study design. 
 
GEM, gemcitabine. 
a. Patients continued to receive trial treatment until disease progression, unacceptable toxicity, 
withdrawal of consent, or trial termination and were discontinued from trial treatment for 
disease progression when new cancer lesions were detected outside the loco-regional area 
(eg, in lung or liver) or when unequivocal evidence of local cancer progression was observed. 
Patients were followed for survival following cessation of trial therapy. 
b. Radiotherapy performed at investigator’s discretion for patients who showed no evidence of 
metastasis, beginning after Cycle 6 with trial treatment dosing interruption. 
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Figure 2. CONSORT diagram for the intent-to-treat analysis of data. 
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Figure 3. Kaplan-Meier Curve of Overall Survival (A) and Progression Free Survival (B). 
 
SUPPLEMENTARY INFORMATION 
Patients and Methods 
Additional Eligibility Criteria 
Patients were aged ≥18 years with an Eastern Cooperative Oncology Group (ECOG) 
performance status (PS) 0–1, adequate hematologic (absolute neutrophil count ≥100,000/µ 
L), hepatic (bilirubin ≤2 x upper limit of normal [ULN]) aspartate transaminase (≤2.5 x ULN), 
and renal (creatinine ≤ 1.5 mg/dL) function, and had not received prior systemic treatment 
for pancreatic cancer. 
Patients were excluded if they had significant cardiovascular disease (e.g. myocardial 
infarction, life-threatening arrhythmia, or QTc >470 msec within 6 months of study entry), a 
clinically significant bleeding disorder, requirement for a strong inhibitor of CYP3A4, or an 
inability to swallow or absorb oral medication. Patients who were pregnant or breastfeeding, 
or who were of childbearing potential but unwilling or unable to use adequate contraception, 
were also excluded. 
Treatment following dose interruption  
Following treatment interruptions for toxicity, missed doses of gemcitabine and/or 
dasatinib/placebo were not replaced. Study treatment was discontinued if there were 
treatment delays of both agents >4 weeks (other than for radiotherapy). If either agent was 
interrupted or discontinued due to drug-related toxicity, patients could continue on the other 
agent alone. If either agent was dose-reduced for toxicity, re-escalation could be considered 
if the adverse event (AE) was determined not to be drug-related. 
Evaluations and Response Assessment 
Pain response was defined as either a decrease of ≥2 points in pain score or 50% decrease 
in analgesia consumption along with stability of the other for ≥4 weeks. Fatigue response 
was defined as a decrease of ≥2 points for ≥4 weeks, with progression defined as ≥2-point 
change for 4 weeks. Both pain and fatigue responses were recorded by the patients once 
weekly. CA19-9 was measured on day 1 of each cycle and response was defined as a ≥50% 
decrease in serum CA19-9 observed for at least 2 consecutive months. 
Statistical Hypothesis and Analyses 
Freedom from distant metastases (FFDM) was defined as the time from randomization until 
the unequivocal appearance of metastatic disease. Pain response, fatigue response, and 
CA19-9 response were analyzed by the Cochran-Mantel-Haenszel test, stratified by 
radiotherapy (pain and fatigue response analyses) and baseline CA19-9 (CA19-9 response 
analyses). Patients who discontinued for any reason other than death or progressive disease 
were followed for survival. 
Results 
Safety Analyses 
Serious AEs were experienced by 53 patients (54%) in the dasatinib group and 48 patients 
(48%) in the placebo group. By the cutoff date of December 2, 2013, a total of 136 patients 
(67%) had died, including 9 patients (9%) in the dasatinib group and 10 patients (10%) in the 
placebo group who died as a result of TEAEs. Causes of deaths due to TEAE in the 
dasatinib and placebo groups included, respectively: cardiac failure and cardio-respiratory 
arrest (2 and 3 patients), gastrointestinal disorders including intestinal obstruction (1 and 1), 
multi-organ failure and sudden death (1 and 1), infections including peritonitis and 
pneumonia (0 and 2), renal failure (1 and 0), and respiratory disorders including pleural 
effusion and respiratory failure (1 and 1). 
 
